CION Ameerpet
Someone has used the word resistant about your cancer, and it lands like a verdict. It is not one. It is a record of how your disease behaved after one particular class of chemotherapy, and what it changes is which treatment comes next — not whether treatment is worth having. If you have been searching platinum resistant ovarian cancer since that appointment, this page explains what the label means, what it does not mean, and what the real options are.
The word is doing a great deal of work in that sentence, and most of it is not the work you think. Platinum-resistant is not a statement about how aggressive your cancer is, and it is not a countdown. It is shorthand for one observed fact: the disease came back within six months of finishing platinum-based chemotherapy. That is the whole of what the label was designed to record.
It matters for a practical reason. Platinum-based chemotherapy is the backbone of ovarian cancer treatment, and the length of the remission it produces is the single best predictor of whether giving it again will work. A long gap suggests the disease will respond a second time. A short gap suggests it will not — and that repeating the same class would hand you the side effects without the benefit. The label exists to change the next prescription, not to describe your future.
It is also blunter than the biology it describes. International consensus groups have moved away from treating platinum-sensitive and platinum-resistant as two sealed boxes, because the interval since your last platinum dose is a continuum, and because your histological subtype, the number of lines you have already had, any lingering side effects and your BRCA or HRD result all change what should happen next. The date on the calendar starts the conversation. It should not finish it. The mechanics of the interval itself are set out on our page explaining the platinum-free interval.
Recurrence within six months of completing platinum-based chemotherapy is called platinum-resistant. Progression during treatment, or within four weeks of the last dose, is called platinum-refractory.
The label records how your disease behaved after one class of chemotherapy. It says nothing about how you will respond to a different class, and it is not a prognosis for you as a person.
A gap of six to twelve months is usually called partially platinum-sensitive, and re-treating with platinum is often still reasonable there. This is why the exact dates are worth checking rather than assuming.
When ovarian cancer returns within six months of platinum-based chemotherapy, the old reflex was to reach for more platinum. The AURELIA trial tested the opposite. Women with platinum-resistant disease were given weekly single-agent non-platinum chemotherapy, with or without anti-angiogenic therapy added to it. Adding the anti-angiogenic drug class almost doubled median progression-free survival, from 3.4 months to 6.7 months, more than doubled the proportion of women whose tumours shrank, and improved abdominal symptoms — although overall survival was not significantly different between the two groups. That trial is the reason non-platinum chemotherapy with an anti-angiogenic agent, rather than another platinum drug, is the usual starting point in this setting. Source: Pujade-Lauraine E et al., Journal of Clinical Oncology (2014); NCCN Ovarian Cancer guidelines.
Platinum resistance is not one situation, and the right next step is not the same for everyone who carries the label. This is roughly the reasoning a medical oncologist works through before naming a treatment.
| Your situation | Usual approach | What it can and cannot do |
|---|---|---|
| First platinum-resistant relapse, feeling reasonably well | Weekly single-agent non-platinum chemotherapy, usually with anti-angiogenic therapy added. | Delays progression and often relieves abdominal symptoms. It is given to control the disease, not to cure it. |
| Progression during platinum, or within four weeks of the last dose | A change of class, an honest conversation about goals, and a clinical trial where one is open. | Response to any chemotherapy is less likely here. Symptom control and quality of life carry more weight in the decision. |
| A gap of six to twelve months since the last platinum dose | Not classed as resistant. Re-treatment with a platinum-based combination is often still reasonable. | This group is frequently mislabelled. Check the two dates before accepting a resistant label. |
| Low-grade serous, clear cell or mucinous histology | Chemotherapy sensitivity is intrinsically lower. Hormonal treatment in low-grade serous disease, and molecular profiling to look for a targetable change. | The label means something different here — the disease may never have been strongly platinum-sensitive to begin with. |
| Already on maintenance therapy at the time of progression | Maintenance is stopped and a new chemotherapy line begins. Earlier BRCA and HRD results still inform what is chosen. | Whether earlier maintenance changes the benefit of later platinum is an active research question, not a settled one. |
| Ascites and abdominal pressure dominating the symptoms | Drainage for symptom relief alongside systemic treatment, with supportive care involved early. | Drainage relieves pressure quickly but does not treat the cancer. It works best as part of a plan, not instead of one. |
*Surgery has a limited role in this setting. The evidence supporting a second operation for recurrence comes from platinum-sensitive relapse, not resistant disease, and surgery here is usually considered for a complication such as bowel obstruction rather than to remove the cancer. Where it is needed, gynaecologic-oncology surgery is coordinated with specialist partner centres, where it is performed and may be billed.
Seven approaches, in roughly the order they are considered. Most women will use more than one of them over time, and the order is decided by subtype, by what has already been given, and by how you are feeling now.
This is the standard backbone. A drug from a different class — taxane, anthracycline or topoisomerase-inhibitor class are the usual choices — given as a single agent, often weekly rather than in a three-weekly block. Weekly schedules at lower individual doses are generally better tolerated, and in resistant disease tolerability is not a secondary consideration: a treatment you cannot continue is not a treatment.
One point is worth stating plainly, because the opposite is often proposed. Combining two non-platinum drugs in this setting increases toxicity without a convincing survival gain over giving them one after the other. Sequential single agents is the evidence-based approach, and it also preserves options — the drug not used today is still available in six months.
Anti-angiogenic treatment works on the tumour's blood supply rather than on the cancer cell itself. Added to weekly single-agent chemotherapy it roughly doubles the time before the disease progresses and increases the chance of a response, and it is particularly useful where ascites is a problem, because it reduces the leakiness of the vessels that produce the fluid.
The trade-offs are real and worth knowing before you start. It raises blood pressure, which usually needs medication. It can cause protein loss in the urine, and it increases the risk of both bleeding and clots. In women with bowel involved by disease, or who have had recent surgery, there is a small risk of a perforation in the bowel wall. Those risks are why it is not simply added for everyone, and why your own history changes the answer.
This is where the field has moved most in the last few years. An antibody-drug conjugate uses an antibody to carry a chemotherapy payload directly to cells carrying a particular surface protein, so more of the drug reaches the tumour and less reaches everything else. In platinum-resistant ovarian cancer, a conjugate directed at folate receptor alpha has improved both progression-free and overall survival compared with chemotherapy in women whose tumours express that receptor strongly — the first time an overall survival gain has been demonstrated in this setting.
Two things follow. First, the tumour has to be tested: these treatments help only where the target is actually present, which is a laboratory question rather than a clinical guess. Second, access and cost vary considerably, and that conversation should happen early and honestly rather than after hopes have been raised. Ask specifically what testing has been done on your tumour block, and what it showed.
Low-grade serous ovarian cancer behaves very differently from the high-grade serous disease that most ovarian cancer information describes. It grows slowly, it is markedly less sensitive to chemotherapy of any kind, and it frequently expresses hormone receptors. In that subtype, hormonal treatment can control disease for long periods with far fewer side effects than chemotherapy, and it is a genuine option rather than a consolation prize.
This is one of the strongest arguments for having the original histology reviewed when a resistant label appears. If a cancer was never chemotherapy-sensitive because of its subtype, calling it platinum-resistant is technically accurate and practically misleading, and it can push treatment toward the wrong class entirely.
Platinum-resistant disease is the setting where a trial is most worth asking about, because it is the setting with the greatest unmet need and therefore the most active research — new conjugates, immune-directed combinations and treatments delivered into the abdominal cavity among them. A trial is not a last resort and not experimentation on the desperate: participants are usually monitored more closely than standard care allows.
Ask early rather than late. Most trials require that you have not already had too many lines of treatment, and that organ function and performance status are reasonable, so eligibility narrows as time passes. Ask which trials are open, where they are running, and what the alternative would be if you did not join.
The binary is softer than it looks, and there are situations where platinum is reasonably given again despite a short interval. If the previous course was stopped early because of an allergic reaction rather than because the disease progressed, if the interval was borderline, or if a later interval turns out longer than an earlier one, sensitivity may be better than the label predicts. Desensitisation protocols also exist for women who reacted to platinum rather than failed it.
This is a judgement call, and one worth a second opinion. It is also the reason to bring precise dates to any consultation: the difference between five months and seven months is the difference between two entirely different treatment pathways.
Ascites, bowel symptoms, pain and fatigue can be treated directly and effectively, and doing so is not giving up. Drainage relieves abdominal pressure within hours. Nutrition support protects strength and makes the next line more tolerable. Good pain control is not a signal that anything has been abandoned. This work runs alongside active treatment, and starting it early produces better results than starting it at the end.
The option nobody offers unprompted is a planned pause. If two consecutive lines have not worked, a break to recover, eat and regain strength is a legitimate medical decision rather than a defeat, and it sometimes leaves you better placed for the next attempt. You are entitled to ask what would happen if you paused, and to get a straight answer. Our page on treating recurrent ovarian cancer sets out how these decisions fit together over time.
Most side effects of treatment in this setting are manageable at home. These are the ones where a phone call the same day changes the outcome, and where waiting for a scheduled review is the wrong instinct.
A temperature of 38°C or above, or shaking chills, at any point after a cycle. Low white cells with infection is an emergency and needs assessment within hours.
Repeated vomiting with a distended abdomen and no wind or stool passing can mean a bowel obstruction. Do not treat this at home with laxatives — it needs a scan.
Rapid distension, breathlessness when lying flat, or clothes tightening over days rather than weeks usually means ascites is reaccumulating. Drainage relieves it quickly.
Ovarian cancer and anti-angiogenic therapy both raise the risk of clots. New breathlessness, chest pain or one swollen, painful leg needs same-day assessment.
Any unusual bleeding, or readings well above your usual range while on anti-angiogenic therapy, should be reported rather than watched.
Sudden severe abdominal pain, particularly with fever, needs urgent assessment. Perforation is uncommon, and it is treatable when found early.
Keep your treating team's number where you can find it at night, and take your treatment summary with you to any emergency visit — the doctor who sees you may not have your records, and the class of drug you are on genuinely changes how you should be managed.
Bring the dates of your last platinum chemotherapy, the scan that showed recurrence, your histopathology report and any BRCA or HRD result. In 45 minutes a medical oncologist can tell you which options genuinely apply to your situation, and what each one is realistically expected to achieve.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If the honest answer is that a treatment would cost you more in side effects than it would buy in time, we will say so plainly.
Six steps, in this order. The commonest avoidable mistake in this pathway is starting a new drug before the first four have been done properly.
The interval runs from the last dose of platinum chemotherapy to documented progression — not from the day you finished all treatment, and not from the day a CA-125 first ticked upward. Five months and seven months lead to different pathways, so precision matters. Ask for the label to be justified with two dates rather than simply asserted.
A rising CA-125 alone is not enough to change a treatment plan. Imaging should confirm and measure the disease, because the scan decides both whether treatment is needed now and what will later be used to judge whether it is working. Treating a number without a corresponding scan is how women end up on the wrong line for months.
The subtype changes the answer more than almost anything else here. Low-grade serous, clear cell and mucinous cancers respond differently to chemotherapy and open different options, and a subtype is sometimes reclassified on review. If the report is more than a couple of years old, ask whether a review is worthwhile.
Germline BRCA testing, tumour BRCA or HRD testing where the blood test was negative, and any receptor testing relevant to biomarker-directed options. These take weeks, and they cannot be done retrospectively if the tissue block was never requested, so the time to order them is now rather than after the next line has failed.
This is the step most often skipped. Ask directly: is this treatment intended to shrink the disease, to hold it still, or to relieve symptoms? What would count as success, and at what point would we stop? A clear answer at the start makes every later decision easier, and it protects you from continuing a treatment out of momentum.
A scan and a CA-125 after two to three cycles, with an agreed plan for what each result would mean. Progression on a scan is a reason to change class rather than to increase the dose. Stable disease with better symptoms is a good outcome and a reason to continue. Write that plan down before the first cycle rather than after the third.
*If a treatment has been proposed before steps two, three and four are complete, that is a reasonable moment to ask for a second opinion — not because anyone has erred, but because those results genuinely change the recommendation.
Two questions bring most women to a second opinion at this point. The first is whether the resistant label is even correct, since it turns on dates that are easy to record loosely. The second, asked more quietly, is whether the next line being proposed is worth what it will cost in side effects and time. Both deserve a proper hour rather than the tail end of a busy clinic.
Your first consultation at CION is free and runs to about 45 minutes. Bring the dates of your last platinum cycle and of the scan that showed recurrence, your histopathology report, any BRCA or HRD result, and a record of every line you have already had. Much of the useful work is unglamorous: reading your own reports back to you, checking whether the interval really was under six months, confirming the subtype, and being specific about what each option is expected to achieve. Every case is discussed at a tumour board rather than decided by one doctor alone.
The division of care should be clear before you decide anything. Chemotherapy and maintenance therapy are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and long-term follow-up. Gynaecologic-oncology surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist partner centres, where they are performed and may be billed. We would rather state that upfront than have you discover it when a bill arrives. The wider picture is set out on our page on ovarian cancer treatment in Hyderabad.
Free and unhurried. Long enough to check the dates, read the reports with you, and say plainly which options genuinely apply to your situation.
Non-platinum chemotherapy, anti-angiogenic therapy and maintenance treatment are given at CION, at whichever of our 35+ centres is closest to where you live.
Genetic counselling, germline BRCA and HRD testing are arranged through CION and ordered before the next line starts rather than after it has failed.
Medical oncology, imaging and pathology review the case together. Decisions for healing, not billing — including the decision not to treat.
The first thing almost everyone does after this conversation is search for a survival figure, and what comes back is both frightening and unreliable. Published survival for platinum-resistant ovarian cancer is drawn largely from trial populations recruited a decade or more ago, averaged across women on their second line and their sixth, mixed across histological subtypes that behave nothing like each other, and gathered before biomarker-directed options existed at all. A median is the midpoint of a wide spread — half of that group did better than it, and some did far better.
None of those figures was calculated on a group that resembles you specifically, and none of them accounts for what your own disease does over the next three months, which is the information that actually matters and which nobody has yet. That is the honest reason an oncologist will not hand you a number when you ask for one, and it is a better reason than evasiveness.
For context rather than prediction, CION publishes its own one-year survival for ovarian cancer alongside the national figure so the comparison is visible rather than implied: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That pair describes the whole treated population at every stage, not women with platinum-resistant recurrence, and it is not a cure rate or a forecast for any individual.
CION ovarian cancer patients alive at one year from diagnosis, across the whole treated population. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
Neither figure describes platinum-resistant recurrence, and neither is a prediction for you. Subtype, previous treatment and how the disease responds next matter far more.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own situation with your treating oncologist.
It means the cancer recurred or progressed within six months of completing platinum-based chemotherapy. That is the entire definition. It is a treatment-planning term, not a prognosis, and not a statement about how aggressive your disease is. Its purpose is to predict one specific thing: whether giving the same class of chemotherapy again is likely to work. A short interval suggests it is not, so the next line comes from a different class. If the disease progressed during treatment or within four weeks of the last dose, the term used is platinum-refractory, which is a more difficult situation. A gap of six to twelve months is a third category, partially platinum-sensitive, where platinum is often still reasonable. The exact dates decide which group you are in, so they are worth confirming rather than assuming.
No. It means one class of chemotherapy is unlikely to work again. Other classes remain available and are used precisely because they act differently, and a proportion of women respond well to them. What changes is realistic expectation: responses in this setting are usually about controlling the disease and relieving symptoms rather than clearing it, and treatment is often given weekly at gentler doses so it can be continued. Adding anti-angiogenic therapy to single-agent chemotherapy has been shown to roughly double the time before progression compared with chemotherapy alone. Where tumour testing identifies a suitable target, biomarker-directed options can do better still. The honest framing is that this is a phase to be managed with a sequence of treatments, rather than the end of treatment.
Sometimes, and it is worth asking rather than assuming not. The sensitive-versus-resistant division is softer than the words suggest. If your previous course was stopped early because of an allergic reaction rather than because the disease progressed, desensitisation protocols allow platinum to be given again safely under supervision. If the interval was borderline, or if a later platinum-free interval turns out longer than an earlier one, sensitivity can be better than the label predicts. Some women who are resistant now respond to platinum again after an intervening non-platinum line has bought time. This is a judgement call rather than a rule, which is why precise dates and a second opinion both matter here more than usual.
By a scan and a CA-125 after two to three cycles, read together and alongside how you actually feel. Imaging is the decisive part: a rising CA-125 on its own is not enough to change a plan, and it can rise transiently in the first weeks of a new treatment. Agree before you start what each possible result would mean. Shrinkage means continue. Stable disease with improved symptoms is a good outcome and also means continue. Clear progression means changing class rather than increasing the dose, because a drug the disease has already grown through does not usually work better in larger amounts. Having that plan written down before the first cycle stops treatment continuing out of momentum rather than evidence.
No honest answer to that question is a single number, and the numbers you will find online will mislead you. Published figures come largely from trial populations recruited many years ago, averaged across women on their second line and their sixth, and mixed across histological subtypes that behave nothing like each other. They predate the biomarker-directed treatments now available. A median is the midpoint of a very wide spread, and a substantial number of women live well beyond it. What actually influences your own outlook is your histological subtype, how many lines you have already had, your general fitness, whether tumour testing has identified a target, and how the disease responds to the next treatment, which nobody yet knows. Ask your oncologist what they are aiming for, rather than for a number.
Usually not as a way of treating the cancer. The evidence supporting a second operation for recurrent ovarian cancer comes from women with platinum-sensitive relapse, a longer interval and disease that can be removed completely. In platinum-resistant disease, surgery has not been shown to improve outcomes and carries a recovery cost that delays systemic treatment. Where an operation is considered, it is generally for a complication such as bowel obstruction rather than to remove the tumour, and less invasive measures are often tried first. If surgery is proposed to you in this setting, ask specifically what it is intended to achieve. At CION, gynaecologic-oncology surgery is coordinated with specialist partner centres, where it is performed and may be billed, rather than done in-house.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology in-house, which covers non-platinum chemotherapy, anti-angiogenic therapy and maintenance treatment across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support and long-term follow-up. Gynaecologic-oncology surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist partner centres, where they are performed and may be billed, and we say so upfront. Bring your treatment dates, the scan showing recurrence, your histopathology report and any molecular results. Every case is discussed at a tumour board, and where the honest advice is to pause rather than to treat, you will be told that plainly.